Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04472494
Recruitment Status : Terminated (Slow accrual)
First Posted : July 15, 2020
Last Update Posted : July 8, 2022
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of intravenous abatacept administered to hospitalized COVID-19 participants with respiratory compromise.

Condition or disease Intervention/treatment Phase
COVID-19 SARS-CoV-2 Biological: Abatacept Other: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 61 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase 2, Randomized, Double-Blind Placebo Controlled Study of Intravenous Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise
Actual Study Start Date : October 14, 2020
Actual Primary Completion Date : August 12, 2021
Actual Study Completion Date : September 15, 2021

Arm Intervention/treatment
Experimental: Abatacept + Standard of care Biological: Abatacept
Specified dose on specified days
Other Names:
  • BMS-188667

Placebo Comparator: Placebo infusion + Standard of care Other: Placebo
Specified dose on specified days

Primary Outcome Measures :
  1. Proportion of participants with composite end point of mechanical ventilation or death prior to or on Day 28 [ Time Frame: Up to 28 days ]

Secondary Outcome Measures :
  1. Change from baseline in the Ordinal 8-point Outcome Scale on Day 28 [ Time Frame: Day 28 ]
  2. All-cause mortality on Day 28 [ Time Frame: Day 28 ]
  3. Proportion of participants alive and free of respiratory failure on Day 28 [ Time Frame: Day 28 ]
  4. Proportion of participants returned to room air by Day 28 [ Time Frame: Up to 28 days ]
  5. Proportion of participants alive and discharged home by Day 28 [ Time Frame: Up to 28 days ]
  6. Proportion of participants with Serious Adverse Events (SAEs) [ Time Frame: Up to 60 days ]
  7. Proportion of participants with serious infections [ Time Frame: Up to 60 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • A confirmed virological diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (by reverse-transcription polymerase chain reaction (RT-PCR)).
  • Hospitalized (or in the Emergency Department awaiting a bed after hospitalization)
  • Respiratory compromise as defined by requirement of oxygen supplementation to maintain oxygen saturation ≥ 93% but not requiring mechanical ventilation
  • Abnormal chest X-ray consistent with COVID-19 and not indicating other serious medical condition that would serve as an exclusionary criteria
  • Women and men must agree to follow specific methods of contraception, if applicable

Exclusion Criteria:

  • Women who are breastfeeding
  • Recent acute infection defined as:

    i) Any acute infection within 60 days prior to randomization that required hospitalization or treatment with parenteral antibiotics (not COVID-19 related) ii) Any acute infection within 30 days prior to randomization that required oral antimicrobial or antiviral therapy

  • History of chronic or recurrent bacterial infection (e.g., chronic pyelonephritis, osteomyelitis, bronchiectasis)
  • Prior exposure to BMS-188667 (abatacept)

Other protocol-defined inclusion/exclusion criteria apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04472494

Layout table for location information
United States, Florida
Alternative Research Associates, Llc
Hialeah, Florida, United States, 33012
Alternative Research Associates
Hialeah, Florida, United States, 33012
United States, Kentucky
Norton Infectious Disease Institute
Louisville, Kentucky, United States, 40202
United States, Massachusetts
Boston Childrens Hospital
Boston, Massachusetts, United States, 02115
Local Institution - 0002
Boston, Massachusetts, United States, 02215
United States, New Jersey
Atlantic Health System
Morristown, New Jersey, United States, 07960
United States, Texas
Methodist Health System Clinical Research Institute (MHSCRI)
Dallas, Texas, United States, 75203
Puerto Rico
CardioPulmonary Research
Guaynabo, Puerto Rico, 00968
Ponce Medical School Foundation
Ponce, Puerto Rico, 00780
Fundacion de Investigacion de Diego
San Juan, Puerto Rico, 00927
Sponsors and Collaborators
Bristol-Myers Squibb
Layout table for investigator information
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Additional Information:
Layout table for additonal information
Responsible Party: Bristol-Myers Squibb Identifier: NCT04472494    
Other Study ID Numbers: IM101-873
U1111-1250-4217 ( Other Identifier: WHO )
First Posted: July 15, 2020    Key Record Dates
Last Update Posted: July 8, 2022
Last Verified: July 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bristol-Myers Squibb:
Coronavirus disease 2019 (COVID-19)
Coronavirus infections
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Tract Infections
Pneumonia, Viral
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents